Green Cross, Abraxis BioScience enter cross licensing agreement

Published: 2007-11-30 06:58:00

Updated: 2007-11-30 06:58:00

Green Cross Corporation and U.S.-based Abraxis BioScience Inc, an integrated and global biopharmaceutical company, announced on November 27 an agreement for the development and commercialization of GCC's five new products, including recombinant blood coagulant XIII factor, interferon alpha and im...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK